# US 2017/0253616 A1 · Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253616 A1
- Document ID: US20170253616A1
- Status: Published application
- Kind: A1
- Application number: 15/597,343
- Filed: 2017-05-17
- Published: 2017-09-07
- Earliest claimed: 2005-04-28
- Assignees: Shionogi & Co., Ltd.; ViiV Healthcare Company
- Applicants: Shionogi & Co., Ltd.; ViiV Healthcare Company
- Inventors: Brian A. JOHNS; Takashi KAWASUJI; Teruhiko TAISHI; Yoshiyuki TAODA
- Web page: https://patentgrep.com/patent/US20170253616A1

## CPC

- C07D 498/14: Ortho-condensed systems
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5365: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 471/04: Ortho-condensed systems
- C07D 471/14: Ortho-condensed systems
- C07D 471/22: in which the condensed systems contains four or more hetero rings
- C07D 498/04: Ortho-condensed systems
- C07D 498/20: Spiro-condensed systems
- C07D 498/22: in which the condensed system contains four or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is to provide a novel compound (I) shown below, having the anti-virus activity; particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. (wherein Z1 is NR4; R1 is hydrogen or lower alkyl; X is a single bond, a hetero atom group selected from O, S, SO, SO2 and NH, or lower alkylane or lower alkenylene in which the hetero atom group may intervene; R2 is optionally substituted aryl; R3 is hydrogen, a halogen, hydroxy, optionally substituted lower alkyl etc; and R4 and Z2 part taken together forms a ring, to form a polycyclic compound; including e.g., a tricyclic or tetracyclic compound.

## Claims

### Claim at position 1

1-56. (canceled)

### Claim 57

A compound of Formula (I-1-1):
wherein the stereochemistry of an asymmetric carbon represented by * is in the R-configuration or S-configuration, or is a mixture thereof;
RX is hydrogen;
R14 is hydrogen;
R3 is hydrogen;
R1 is hydrogen;
each R is independently a halogen;
m is an integer of 0 to 3;
ring A is an unsubstituted bicyclic ring residue having a chemical formula C6H9NO; and
the carbon represented by * is directly bonded to an oxygen.

### Claim 58 (depends on 57)

The compound of claim 57, wherein ring A includes two carbon-nitrogen single bonds, two carbon-oxygen single bonds, five carbon-carbon single bonds, and nine carbon-hydrogen single bonds.

### Claim 59 (depends on 58)

The method according to claim 58, wherein one of the rings of the unsubstituted bicyclic ring of ring A is
wherein Z is oxygen.

### Claim 60 (depends on 59)

The compound of claim 59, wherein each R is fluorine.

### Claim 61 (depends on 60)

The compound of claim 60, wherein m is 2 or 3.

### Claim 62 (depends on 61)

The compound of claim 61, wherein a fluorine is at the para position and a fluorine is at the orthe position.

### Claim 63 (depends on 62)

The compound of claim 62 wherein the compound has a diastereomeric purity of greater than 10:1.

### Claim 64 (depends on 62)

The compound of claim 62, wherein the asymmetric carbon represented by * is in the R-configuration.

### Claim 65 (depends on 62)

The compound of claim 62, wherein the compound has an enantiomeric excess of greater than 95%.

### Claim 66 (depends on 57)

A pharmaceutical composition comprising the compound of claim 57 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable diluent.

### Claim 67 (depends on 59)

A pharmaceutical composition comprising the compound of claim 59 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable diluent.
